Rapidly increasing pace of life, change in lifestyle, higher stress levels, etc., are few of the major factors to which the increasing prevalence of cluster headache scan be attributed. Further, unhealthy dietary intake, smoking, alcoholconsumption and growing levels of pollutionare few other factors which are expected to fuel the incidence of cluster headache problem. The Therapeutic pipeline of cluster headache is expected to grow in future with the participation of various pharmaceutical companies that are focusing on developing novel drugs for curing the problem of cluster headache. As per WHO, problem of cluster headache is more common in men, as compared to women, and mostly in people in the age group of 20 to 40 years. According to a recently published NCBI paper, one of every 1,000 adults in the U.S. experiences the problem of cluster headache. In spite of the problem of cluster headache being very common, it has mostly been under-recognized and has been overlooked.
Cluster headache, also called ashistamine headache, is a primary headachedisorder of the nervous system, and is a headache of constant nature, experienced over a prolonged period of time, occurring mostly at night during sleep. According to the studies conducted by International Headache society (IHS), during cluster headache the patient experiences very severe pain, which occurs for duration of 15 to 180 minutes, once a day. Lacrimation, facial sweating, eyelid edema, restlessness, runny nose, rhinorrhea, ptosis, one-sided pain, nasal congestion, miosis & conjunctivitis, are few of the symptoms ofdiagnosing cluster headache.
Request for Table of Content at: https://www.psmarketresearch.com/market-analysis/cluster-headache-therapeutics-pipeline-analysis/toc-sample
Some of the companies having a pipeline of cluster headache therapeutics include Eliy-lilly& Company, Teva pharmaceuticals industries Ltd, Winston laboratories,Gilead Sciences, Inc., Galapagos NV, Astellas Pharma, Abbvie, Inc., Bexalta US, Inc., Optimer pharmaceutical LLC.